US 8,420,386 B2Granted

Transposon-based targeting system

AssigneeMax-Delbruck-Centrum Fur Molekulare Medizin (Mdc)

InventorsZoltan Ivics, Zsuzsanna Izsvak

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention relates to a targeting system comprising, preferably as distinct components (a) a transposon which is devoid of polynucleotide encoding a functional transposase comprising (aa) a polynucleotide of interest and; (ab) a DNA sequence specifically recognized by a DNA binding domain; and (ba) a fusion protein comprising (i) said DNA binding domain; or (ii) a (poly)peptide binding domain binding to a (poly)peptide comprising said DNA binding domain; and (iii) a DNA targeting domain; or (iv) a (poly)peptide binding domain that binds to a cellular or engineered (poly)peptide that comprises a DNA targeting domain; or (bb) a polynucleotide encoding the fusion protein of (ba); and (ca) a transposase or a fragment or derivative thereof having transposase function; or (cb) a polynucleotide encoding the transposase or fragment or derivative thereof having transposase function of (ca).

Claims20

Dependent claims

A targeting system comprising

(a) a first vector comprising a transposon which is devoid of a polynucleotide encoding a functional transposase comprising
(aa) a polynucleotide of interest;
and
(ab) a DNA sequence specifically recognized by a DNA binding domain, wherein the DNA sequence does not have inverted repeats of a transposon;
and
(b) a second vector comprising a polynucleotide encoding a fusion protein, wherein the fusion protein nor the components recited in (i)-(iv) do not directly mediate integration of a transposon, comprising
(i) said DNA binding domain;
or
(ii) a (poly)peptide binding domain binding to a (poly)peptide comprising said DNA binding domain;
and
(iii) a DNA targeting domain;
or
(iv) a (poly)peptide binding domain that binds to a cellular or engineered (poly)peptide that comprises a DNA targeting domain;
and
(c) a third vector comprising a polynucleotide encoding a transposase or a fragment or derivative thereof having transposase function.

12 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/544,971Filed 10 Feb 2004
Priority: EP 0300263810 Feb 2003
Published: US 2006/0258603 A116 Nov 2006
Granted: 16 Apr 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C12N 15/90
Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation: stable introduction of foreign DNA…
A61P 3/06
Drugs for disorders of the metabolism: antihyperlipidemics
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 7/00
Drugs for disorders of the blood or the extracellular fluid